The Global Multiple Cancer Monoclonal Antibodies Market Size is valued at 61.64 billion in 2022 and is predicted to reach 154.24 billion by the year 2031 at a 10.94% CAGR during the forecast period for 2023-2031.
Cancer monoclonal antibodies are specific antibodies with identical immune cells that are clones of a single parent cell directed to specific cellular targets. Thus, monoclonal antibodies are preciously customizable due to their unique nature and play a crucial role in treating target-specific cancerous cells. Therefore, monoclonal antibodies technology is proven to be more effective than other cancer therapies.
The increasing incidence of cancer disease among the population is driving the growth of the market. For instance, as per the World Health Organization, cancer is the second leading cause of death worldwide, accounting for around 9.6 million deaths in the year 2018. Multiple cancers, including lung cancer, colorectal cancer, prostate cancer, and liver cancer, are the most common types of cancer among men, while breast cancer, cervical cancer, colorectal cancer, and thyroid cancer are the most common among women. Additionally, increasing spending on research and development by multinational pharmaceutical companies is expected to create lucrative market growth. However, the high cost of treatment therapy and drug development may restrain the growth of the market.
Market Segmentation
The Global Multiple Cancer Monoclonal Antibodies market is segmented on the basis of product type, indication type, and region. Based on the service, the market is divided into Cetuximab, Nivolumab, Atezolizumab, Ramucirumab, Pembrolizumab, Pembrolizumab Companion Diagnostic, Ipilimumab, and Cancer Biosimilar Drugs (Bevacizumab, Trastuzumab, Nimotuzumab, etc.). On the basis of indication type, the market is divided into Lung Cancer, Bladder Cancer, Breast cancer, Endometrial cancer, Ovarian cancer, Oesophageal cancer, Prostate cancer, Multiple Myeloma, Lymphoma, Renal Cell Cancer, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and the Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period
Competitive Landscape
Some Of The Key Players In The Multiple Cancer Monoclonal Antibodies Market:
- Abbvie,
- Amgen,
- Bayer HealthCare,
- Biogen Idec,
- Eli Lilly,
- Genmab,
- Gilead Sciences,
- GlaxoSmithKline,
- Novartis,
- Pfizer,
- Roche,
- Seattle Genetics,
Multiple Cancer Monoclonal Antibodies Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 61.64 billion |
|
Revenue Forecast In 2031 |
USD 154.24 billion |
|
Growth Rate CAGR |
CAGR of 10.94% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product Type, Indication Type |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Abbvie, Amgen, Bayer HealthCare, Biogen Idec, Eli Lilly, Genmab, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Roche, and Seattle Genetics, among others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
